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Brief Technique ReportsSynthetic biodegradable hydrogel (PleuraSeal) sealant for sealing
of lung tissue after thoracoscopic resectionAmulya K. Saxena, MD, Graz, AustriaFIGURE 1. The PleuraSeal lung sealant system. The 2 components, poly-
ethylene glycol and trilysine, are sprayed with the MicroMist spray applica-
tor, which is attached to a surgical air pump. The applicator can be passed
through a port, and the tip is positioned at a distance of 2 cm from the tissue
site to be sealed.Postoperative air leaks are a major cause of morbidity after
lung resections. A variety of biologic and synthetic materials
have been used to seal resected lung tissue to address this
problem; however, none of the products have been proved
effective. Between the 2 groups, synthetic materials have
found a preference because they overcome the issues that
are associated with the manufacture, storage, and application
of biologic substitutes.1,2 The use of a novel synthetic biode-
gradable hydrogel that can be applied as a spray to seal lung
tissue after thoracoscopic resection is presented.
CLINICAL SUMMARY
A 14-year-old female patient presented with recurrent
pneumothorax caused by rupture of a left solitary apical pul-
monary bleb. A thoracoscopic approach was chosen to man-
age the pathology. The patient was placed in a right- lateral
decubitus position, and the lesion was identified with a
5-mm 30 scope. The tissue around the 3-cm-diameter bleb
was held with graspers and was resected with endoscopic
linear staplers, after which the hydrogel sealant was used
prophylactically. PleuraSeal lung sealant (Covidien, Mans-
field, Mass) was applied as a spray on the edge of the stapled
pulmonary tissue by using the MicroMist applicator (Covi-
dien) through a 5-mm port. The MicroMist applicator is
a 1.5-cm-long and 3.3-mm-diameter multilumen cannula
that uses filtered air to spray the sealant and is used in con-
jugation with a confluent surgical air pump (Figure 1). The
PleuraSeal formed a visible blue seal as its 2 liquid compo-
nents were sprayed on the site of resection and set as a gel
(Figure 2). No chest tube was placed. The patient was dis-
charged after 3 days, and regular follow-up examinations
during a 1-year period after surgical intervention were
uneventful (no pneumothorax or fluid accumulations).From the Department of Pediatric and Adolescent Surgery, Medical University of
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PleuraSeal is intended for use as an adjunct to the standard
closure techniques of underlying pulmonary parenchyma
and visceral pleura. It uses advanced hydrogel technology
to provide an immediate airtight seal that is effective during
surgical intervention and throughout the lung healing period.
The seal is maintained over a 4- to 8-week period, after
which the hydrogel hydrolyzes to liberate polyethylene gly-
col (PEG) molecules, which are cleared by the kidneys.
PleuraSeal is a 100% synthetic biodegradable hydrogel
that eliminates the risk of allergic reaction, immune re-
sponse, and viral transmission. Because it is an inert mate-
rial, it does not support bacterial growth.3 The absence of
latex in this hydrogel furthermore permits its safe use in pa-
tients with known allergy to latex. PleuraSeal is stored at or
less than 25C, which makes the transport, storage, and use
of its components easier than those of fibrin glue.
The PleuraSeal surgical sealant system consists of 2 liquid
components: PEG ester and trilysine amine. The first com-
ponent, PEG, is a water-soluble, nontoxic, and biocompati-
ble component with reactive linkages. PEG is supplied as
a transparent blue solution and imparts the blue color to
the polymerized hydrogel. The second component, trilysine,
is sourced from L-lysine, which comes from the fermenta-
tion of cane molasses or tapioca starch and is plant derived,
but the final trilysine product is also considered synthetic.ery c February 2010
FIGURE 2. Thoracoscopic view of the transparent blue seal after spray ap-
plication of PleuraSeal lung sealant at the site of pulmonary tissue resection
(with an endoscopic linear stapler).
Brief Technique ReportsWhen PEG and trilysine solutions are mixed, they polymer-
ize almost instantaneously to form a 3-dimensional absorb-
able hydrogel.4 The polymerization is a gentle process on
tissue with no exothermic reaction and minimal tissue re-
sponse. The rapid influx of the liquid form of PEG and trily-
sine into tissue crevices enables hydrogel formation that has
a strong mechanical bond with underlying tissue. The com-
bination of high cohesive strength and flexibility of the hy-
drogel renders it the capability to accommodate natural
expansion and contraction of the underlying lung tissue.5
For proper spray application during thoracoscopic proce-
dures, theMicroMist applicator tip should be held 2 cm fromFrom the Wessex Cardiothoracic Centre, Southampton University Hospitals NHS
Trust, Southampton, United Kingdom.
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The Journal of Thoracic and Cathe target site, and the sealant should be applied in a way to
create a 1- to 2-mm-thick hydrogel. The application site
should be prepared by removing all blood and fluids before
spraying. When compared with the injection technique, the
spray applicator enables uniform spraying of the sealant to
cover a larger surface area and enables paucity between
spray intervals without clogging of the applicator tip or
denaturing of the sealant components.
PleuraSeal has received the CE mark (Conformite´
Europe´enne) for lung sealing and has been available in the
European Union since 2006; however, at present, it is not
for sale in the United States. A single-use application kit
costs approximately V400. PleuraSeal offers a novel off-
the-shelf synthetic biodegradable lung sealant that can be
applied as a visible blue-colored spray and can be used as
a prophylactic adjunct in thoracoscopic lung procedures.References
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post–cardiac surgery sternal instabilityHunaid A. Vohra, MRCS, MD, Robert N. Whistance, MRCS, Marcob Bolgeri, MRCS, and
Geoffrey M. K. Tsang, MD, FRCS(CTh), Southampton, United KingdomMedian sternotomy is the most frequently used incision in
cardiac surgery. Sternal instability is a chronic complicationfollowing malunion or nonunion. This is traditionally man-
aged by reopening the sternum completely, removing frac-
tured or loose metalwork, and rewiring. Reoperation may
be hazardous due to adhesions, adjacent right ventricle,
and patent grafts. We report for the first time the application
of nitinol thermoreactive Flexigrips (Preasidia SRL, Bolo-
gna, Italy) in the management of sternal instability without
the need to enter the mediastinum.
CLINICAL SUMMARY
Patient 1
An 80-year-old man with FEV1 of 0.8L was admitted with
unstable angina. After an urgent coronary angiogram, he un-
derwent quadruple coronary artery bypass grafting (CABG;rdiovascular Surgery c Volume 139, Number 2 497
